Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shanghai Fosun Pharmaceutical Group's subsidiary to acquire 28.146 pct of Jinzhou-based pharmaceutical company


Friday, 28 Feb 2014 07:00pm EST 

Shanghai Fosun Pharmaceutical Group Co Ltd:Says wholly owned subsidiary, a Shanghai-based pharmaceutical industry development company, signed a contract on Feb. 28 with a Xinjiang-based company, to acquire a 28.146 pct stake in a 70 pct-owned subsidiary, a Jinzhou-based pharmaceutical company.Subsidiary will acquire a 23 pct stake in a Jinzhou-based pharmaceutical company for up to 1,524.90 mln yuan as the first tranche of acquisition.Subsidiary will acquire the remaining 5.146 pct in Jan. 1, 2019 to Jan. 15, 2019, for 341,179,800 yuan.